Literature DB >> 6093530

Systemic candidiasis in cancer patients.

A W Maksymiuk, S Thongprasert, R Hopfer, M Luna, V Fainstein, G P Bodey.   

Abstract

Two hundred thirty-five fungal infections occurred in patients with malignant diseases over a four-year period. One hundred eighty-eight were due to Candida species and Torulopsis glabrata and are reviewed herein. The frequency was highest in patients with acute leukemia (11.9 per 100 registrations) with a frequency of 0.8 per 100 registrations in all cancer patients at this institution. Three or more predisposing factors were present in more than 50 percent of the cases; antecedent myelosuppression, chemotherapy, and antibiotic therapy were most common. Blood cultures were positive in only 35 percent of patients with disseminated candidiasis. Twenty-nine of 55 patients (53 percent) had candidemia without identifiable organ infection recovered. Eleven were given no systemic antifungal therapy and recurrence of infection was documented in two patients. Only six (4.5 percent) of 133 patients with proved deep organ infections recovered. Respiratory failure was the clinical cause of death in 62 percent of patients. Clinical features, cultures, and serologic tests were usually of no assistance in establishing the diagnosis early in the course of the infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093530

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  60 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

2.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

3.  Diagnosis of disseminated candidiasis in hospitalized patients using the Cand-Tec latex agglutination assay.

Authors:  M L Sanchez; M A Pfaller; I Cabezudo; M Bale; B Buschelman
Journal:  Mycopathologia       Date:  1992-06       Impact factor: 2.574

Review 4.  False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy.

Authors:  A Borst; A T A Box; A C Fluit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

5.  Clearance of Candida colonizing the urinary bladder by a two-day amphotericin B irrigation.

Authors:  C C Hsu; B Ukleja
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

6.  Candida endophthalmitis: clinical presentation, treatment and outcome in 23 patients.

Authors:  S Schmid; A C Martenet; O Oelz
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

7.  Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

8.  Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media.

Authors:  Benjamin J George; Lynn L Horvath; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

9.  Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.

Authors:  G P Bodey; E Anaissie; J Gutterman; S Vadhan-Raj
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

10.  Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis.

Authors:  M E Bougnoux; C Hill; D Moissenet; M Feuilhade de Chauvin; M Bonnay; I Vicens-Sprauel; F Pietri; M McNeil; L Kaufman; J Dupouy-Camet
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.